DEDAS dose escalation study of desmoteplase in acute ischemic stroke -- twin study to DIAS. phase 2 trial for safety and efficacy among patients with P/D mismatch on mRI 3-9 hours after onset of acute ischemic stroke. (Tony Furlan). 39 patients, doses 90 and 125 ug/kg, NIHSS baseline 4-20. There were no sICH cases Reperfusion occurred in 37.5 %, including 18 % of lower dose patients and 53% of higher dose patients. Good outcome occurred in 25 % of placebo, 28 % of lower dose patients, and
